Clinical Topics & News

Improving Treatment Options for Chronic Myelogenous Leukemia

Dr. Benjamin Powers and Dr. Suman Kambhampati discuss the improvements they have seen in the survival of patients with CML and how genetics and other factors play a role in treating the disease.

Publish date: August 18, 2014
Author(s):
Alyana Alfaro

 

Recently, Federal Practitioner talked with Benjamin Powers, MD, and Suman Kambhampati, MD, about factors that come into play when treating patients with chronic myelogenous leukemia (CML) and the dramatic improvements in treatment that have been made. To find out more about these factors and improvements, read Blast Phase Chronic Myelogenous Leukemia from the August 2014 issue.

Dr. Powers is a fellow and Dr. Kambhampati is an associate professor of medicine, both in the Department of Internal Medicine, Division of Hematology/Oncology, at the University of Kansas Medical Center in Kansas City, Kansas. Dr. Kambhampati is also a staff physician in the Hematology/Oncology Division at the Kansas City VAMC in Kansas City, Missouri.

Recommended Reading

A New Treatment for Type 2 Diabetes; The Problem of Chemotherapy for Oldest-Old Patients; Clarithromycin and Cardiovascular Events
AVAHO
Study Finds Decline in Suicide Among Veterans; Sequestration and the NIH; Improving Cancer Care for African Americans; Grants Extend the Reach of Health Care for Veterans
AVAHO
Know Your Prostate
AVAHO
A Simpler, Faster Way to Insert Feeding Tubes; Gout Attacks in the Hospital; Nutrition Labels in Menus; Uterine Cancer and Weight
AVAHO
Performance Status: In the Eye of the Beholder?
AVAHO
Cancer Drugs Increase Rate of Preventable Hospital Admissions
AVAHO
Follow-up on Hematuria
AVAHO
Systemic Treatment and Outcomes of Metastatic Pancreatic Cancer
AVAHO
Prostate Cancer Survivorship Care
AVAHO
New Breast Cancer Research Group Aims To Improve Veteran Survival Rates
AVAHO

Related Articles

  • Clinical Topics & News

    Blast Phase Chronic Myelogenous Leukemia

    Author:
    Benjamin Powers, MD
    Suman Kambhampati, MD

    The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast phase of chronic myelogenous...